Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00079001
Other study ID # CALGB-90202
Secondary ID U10CA031946CAN-N
Status Completed
Phase Phase 3
First received
Last updated
Start date January 2004
Est. completion date October 2014

Study information

Verified date April 2020
Source Alliance for Clinical Trials in Oncology
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RATIONALE: Zoledronate may prevent or decrease skeletal (bone)-related events (such as pain or fractures) caused by bone metastases and androgen deprivation therapy. It is not yet known whether treatment with zoledronate is effective in preventing bone-related events in patients who have prostate cancer and bone metastases.

PURPOSE: This randomized phase III trial is studying how well zoledronate works in preventing bone-related events in patients who are receiving androgen deprivation therapy for prostate cancer and bone metastases.


Description:

Zoledronic acid decreases the risk of skeletal related events in men with prostate cancer metastatic to bone and disease progression after primary hormonal therapy.

This study is designed to evaluate whether earlier treatment with zoledronic acid will further decrease the risk of skeletal related events. This is a randomized, double-blind, placebo-controlled, multicenter study followed by an open-label study. Patients are stratified according to ECOG performance status (0-1 vs 2), prior skeletal-related event (no vs yes), and serum alkaline phosphatase (< upper limit of normal [ULN] vs ≥ ULN).

The primary objective of the study is to determine whether treatment with zoledronic acid at the time of initiation of androgen deprivation therapy for metastatic prostate cancer will delay the time to first skeletal related event. The secondary objective of the study is to compare the effect of treatment with zoledronic acid to placebo on overall survival (OS), progression-free survival (PFS) and toxicity in men receiving androgen deprivation therapy for metastatic prostate cancer.

Patients are randomized to 1 of 2 treatment arms. Treatment continues in the absence of disease progression or a skeletal-related event. All patients receive concurrent androgen deprivation therapy with a GnRH agonist. Patients also receive oral calcium and (vitamin D) supplements daily. Patients progressing to androgen-independent prostate cancer proceed to the open-label therapy with zoledronic acid IV. Treatment continues for 3 weeks in the absence of disease progression or the first skeletal-related event.

Patients are followed periodically for approximately 10 years after entry on the study.


Other known NCT identifiers
  • NCT00698308

Recruitment information / eligibility

Status Completed
Enrollment 645
Est. completion date October 2014
Est. primary completion date July 2012
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility 1. Histologic Documentation: Histologic documentation of prostate adenocarcinoma. Patients with small cell, neuroendocrine, or transitional cell carcinomas are not eligible.

2. Staging: At least one bone metastasis by radiographic imaging (bone scan, magnetic resonance imaging, computed tomography, or plain radiographs). Indeterminate lesions should be confirmed by a second imaging method. Imaging to document bone metastases is to be completed either within 12 weeks before registration or within 12 weeks before initiating androgen deprivation therapy for bone metastases.

3. Hormone Therapy

- While on this study, patients must receive androgen deprivation therapy (ADT) for treatment of prostate cancer. Androgen deprivation therapy may have begun prior to enrollment on this study; however patients must have initiated ADT = 6 months prior to enrollment.

- Androgen deprivation therapy is defined as bilateral orchiectomy or gonadotropin- releasing hormone (GnRH) agonist with or without an antiandrogen.

- Patients treated with intermittent androgen deprivation therapy are not eligible except for patients concurrently enrolled in SWOG-9346/INT-0162/CALGB 9594, Phase III Study of Intermittent Androgen Deprivation in Patients with Stage D2 Prostate Cancer.

4. Prior Treatment:

- Hormone therapy at any point prior to 6 months before enrollment is prohibited. This includes any of the following treatments:

- orchiectomy,

- GnRH agonist (e. g., leuprolide, goserelin, triptorelin),

- estrogen therapy,

- antiandrogen (e. g., bicalutamide, flutamide, nilutamide), or

- any other therapy known to lower testosterone level or inhibit testosterone effect.

- Prior neoadjuvant and/or adjuvant hormone therapy is allowed provided that the duration of hormone therapy was six months or less and the hormone therapy was discontinued more than 6 months prior to study entry.

- No prior treatment with a bisphosphonate

- No prior treatment with denosumab

- No prior treatment with radiopharmaceuticals

- = 4 weeks since completion of prior radiation therapy with at least one bone metastasis present that has NOT been radiated.

5. ECOG (CTC) performance status 0-2

6. Age: = 18 years

7. Required Initial Laboratory Data:

- Calculated Creatinine Clearance = 30 mL/min

- Corrected serum calcium = 8.0 mg/dL (2.00 mmol/L) and <11.6 mg/dL (2.90 mmol/L)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
zoledronic acid
Given IV
Other:
placebo
Given IV
Drug:
androgen deprivation therapy
Patients concurrently enrolled on the Phase III study of intermittent androgen deprivation in patients with stage D2 prostate cancer will receive androgen deprivation therapy per SWOG-9346. All other patients will receive androgen deprivation therapy at a standard dose and schedule throughout the study.
GnRH agonist
Patients concurrently enrolled on the Phase III study of intermittent androgen deprivation in patients with stage D2 prostate cancer will receive the GnRH agonist per SWOG-9346. All other patients will receive GnRH agonist at a standard dose and schedule throughout the study.
Dietary Supplement:
Calcium supplement
Patients will receive 500 mg by mouth daily of a calcium supplement or a combination tablet containing approximately 500 mg elemental calcium and 400-500 IU vitamin D by mouth daily.
Vitamin D
Patients will receive a multivitamin tablet containing 400-500 IU vitamin D by mouth daily or a combination tablet containing approximately 500 mg elemental calcium and 400-500 IU vitamin D by mouth daily.

Locations

Country Name City State
Canada Cross Cancer Institute at University of Alberta Edmonton Alberta
Canada London Regional Cancer Program at London Health Sciences Centre London Ontario
Canada University of British Columbia Vancouver British Columbia
United States Kapiolani Medical Center at Pali Momi 'Aiea Hawaii
United States Hickman Cancer Center at Bixby Medical Center Adrian Michigan
United States Lovelace Medical Center - Downtown Albuquerque New Mexico
United States University of New Mexico Cancer Center Albuquerque New Mexico
United States American Fork Hospital American Fork Utah
United States Island Hospital Cancer Care Center at Island Hospital Anacortes Washington
United States Langlade Memorial Hospital Antigo Wisconsin
United States Rush-Copley Cancer Care Center Aurora Illinois
United States Good Samaritan Hospital of Maryland Baltimore Maryland
United States Greenebaum Cancer Center at University of Maryland Medical Center Baltimore Maryland
United States Kaiser Permanente at Woodlawn Medical Center Baltimore Maryland
United States Union Memorial Hospital Baltimore Maryland
United States Veterans Affairs Medical Center - Baltimore Baltimore Maryland
United States Mary Bird Perkins Cancer Center - Baton Rouge Baton Rouge Louisiana
United States St. Joseph Cancer Center Bellingham Washington
United States Mountainview Medical Berlin Vermont
United States Billings Clinic - Downtown Billings Montana
United States CCOP - Montana Cancer Consortium Billings Montana
United States Hematology-Oncology Centers of the Northern Rockies - Billings Billings Montana
United States St. Vincent Healthcare Cancer Care Services Billings Montana
United States Dana-Farber/Brigham and Women's Cancer Center Boston Massachusetts
United States Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute Boston Massachusetts
United States Massachusetts General Hospital Boston Massachusetts
United States Wood County Oncology Center Bowling Green Ohio
United States Bozeman Deaconess Cancer Center Bozeman Montana
United States Olympic Hematology and Oncology Bremerton Washington
United States Kings County Hospital Center Brooklyn New York
United States SUNY Downstate Medical Center Brooklyn New York
United States Roswell Park Cancer Institute Buffalo New York
United States Veterans Affairs Medical Center - Buffalo Buffalo New York
United States Highline Medical Center Cancer Center Burien Washington
United States Fletcher Allen Health Care - University Health Center Campus Burlington Vermont
United States Fairview Ridges Hospital Burnsville Minnesota
United States St. James Healthcare Cancer Care Butte Montana
United States Sandra L. Maxwell Cancer Center Cedar City Utah
United States Louis A. Weiss Memorial Hospital Chicago Illinois
United States University of Chicago Cancer Research Center Chicago Illinois
United States University of Illinois Cancer Center Chicago Illinois
United States Veterans Affairs Medical Center - Chicago Westside Hospital Chicago Illinois
United States MetroHealth Cancer Care Center at MetroHealth Medical Center Cleveland Ohio
United States Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center Columbus Ohio
United States New Hampshire Oncology - Hematology, PA at Payson Center for Cancer Care Concord New Hampshire
United States Mercy and Unity Cancer Center at Mercy Hospital Coon Rapids Minnesota
United States Bay Area Hospital Coos Bay Oregon
United States Heartland Oncology and Hematology Council Bluffs Iowa
United States Josephine Ford Cancer Center at Henry Ford Hospital Detroit Michigan
United States CCOP - Duluth Duluth Minnesota
United States Duluth Clinic Cancer Center - Duluth Duluth Minnesota
United States Miller - Dwan Medical Center Duluth Minnesota
United States Duke Cancer Institute Durham North Carolina
United States Veterans Affairs Medical Center - East Orange East Orange New Jersey
United States CCOP - Hematology-Oncology Associates of Central New York East Syracuse New York
United States Shore Regional Cancer Center at Memorial Hospital - Easton Easton Maryland
United States Fairview Southdale Hospital Edina Minnesota
United States Elkhart Clinic, LLC Elkhart Indiana
United States Elkhart General Hospital Elkhart Indiana
United States Michiana Hematology-Oncology, PC - Elkhart Elkhart Indiana
United States Elmhurst Memorial Hospital Elmhurst Illinois
United States Green Bay Oncology, Limited - Escanaba Escanaba Michigan
United States Center for Cancer Care at Exeter Hospital Exeter New Hampshire
United States Kaiser Permanente Medical Center - Fair Oaks Fairfax Virginia
United States Hembree Mercy Cancer Center at St. Edward Mercy Medical Center Fort Smith Arkansas
United States Fredericksburg Oncology, Incorporated Fredericksburg Virginia
United States Mercy and Unity Cancer Center at Unity Hospital Fridley Minnesota
United States Saint Francis Cancer Treatment Center at Saint Francis Memorial Health Center Grand Island Nebraska
United States Big Sky Oncology Great Falls Montana
United States Great Falls Clinic - Main Facility Great Falls Montana
United States Sletten Cancer Institute at Benefis Healthcare Great Falls Montana
United States Green Bay Oncology, Limited at St. Mary's Hospital Green Bay Wisconsin
United States Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center Green Bay Wisconsin
United States St. Mary's Hospital Medical Center - Green Bay Green Bay Wisconsin
United States St. Vincent Hospital Regional Cancer Center Green Bay Wisconsin
United States CCOP - Greenville Greenville South Carolina
United States Greenville Hospital Cancer Center Greenville South Carolina
United States Self Regional Cancer Center at Self Regional Medical Center Greenwood South Carolina
United States John R. Marsh Cancer Center at Washington County Hospital Hagerstown Maryland
United States St. Peter's Hospital Helena Montana
United States Veterans Affairs Medical Center - Hines Hines Illinois
United States Cancer Research Center of Hawaii Honolulu Hawaii
United States Hawaii Medical Center - East Honolulu Hawaii
United States Kapiolani Medical Center for Women and Children Honolulu Hawaii
United States OnCare Hawaii, Incorporated - Kuakini Honolulu Hawaii
United States OnCare Hawaii, Incorporated - Lusitana Honolulu Hawaii
United States Queen's Cancer Institute at Queen's Medical Center Honolulu Hawaii
United States Straub Clinic and Hospital, Incorporated Honolulu Hawaii
United States New Hampshire Oncology - Hematology, PA - Hooksett Hooksett New Hampshire
United States Baylor University Medical Center - Houston Houston Texas
United States Ben Taub General Hospital Houston Texas
United States St. Luke's Texas Cancer Institute at St. Luke's Episcopal Hospital Houston Texas
United States Veterans Affairs Medical Center - Houston Houston Texas
United States Hutchinson Area Health Care Hutchinson Minnesota
United States Indiana University Melvin and Bren Simon Cancer Center Indianapolis Indiana
United States William N. Wishard Memorial Hospital Indianapolis Indiana
United States Holden Comprehensive Cancer Center at University of Iowa Iowa City Iowa
United States Veterans Affairs Medical Center - Iowa City Iowa City Iowa
United States Dickinson County Healthcare System Iron Mountain Michigan
United States Borgess Medical Center Kalamazoo Michigan
United States Bronson Methodist Hospital Kalamazoo Michigan
United States West Michigan Cancer Center Kalamazoo Michigan
United States Glacier Oncology, PLLC Kalispell Montana
United States Kalispell Medical Oncology at KRMC Kalispell Montana
United States Kalispell Regional Medical Center Kalispell Montana
United States Provena St. Mary's Regional Cancer Center - Kankakee Kankakee Illinois
United States Good Samaritan Cancer Center at Good Samaritan Hospital Kearney Nebraska
United States Columbia Basin Hematology Kennewick Washington
United States Kinston Medical Specialists Kinston North Carolina
United States Howard Community Hospital Kokomo Indiana
United States La Grange Memorial Hospital La Grange Illinois
United States Center for Cancer Therapy at LaPorte Hospital and Health Services La Porte Indiana
United States Kaiser Permanente Mid-Atlantic Medical Group-Largo Medical Facility Largo Maryland
United States CCOP - Nevada Cancer Research Foundation Las Vegas Nevada
United States Nevada Cancer Institute Las Vegas Nevada
United States University Medical Center of Southern Nevada Las Vegas Nevada
United States Leesburg Regional Medical Center Leesburg Florida
United States Lima Memorial Hospital Lima Ohio
United States St. Rita's Medical Center Lima Ohio
United States Cancer Resource Center - Lincoln Lincoln Nebraska
United States Arkansas Cancer Research Center at University of Arkansas for Medical Sciences Little Rock Arkansas
United States Logan Regional Hospital Logan Utah
United States Veterans Affairs Medical Center - Loma Linda (Pettis) Loma Linda California
United States Dana-Farber Cancer Institute at Londonderry Londonderry New Hampshire
United States Lowell General Hospital Lowell Massachusetts
United States Southeastern Regional Medical Center Lumberton North Carolina
United States Lynchburg Hematology-Oncology Clinic Lynchburg Virginia
United States Elliot Regional Cancer Center at Elliot Hospital Manchester New Hampshire
United States Holy Family Memorial Medical Center Cancer Care Center Manitowoc Wisconsin
United States HealthEast Cancer Care at St. John's Hospital Maplewood Minnesota
United States Minnesota Oncology Hematology, PA - Maplewood Maplewood Minnesota
United States Bay Area Cancer Care Center at Bay Area Medical Center Marinette Wisconsin
United States Northwest Ohio Oncology Center Maumee Ohio
United States Cardinal Bernardin Cancer Center at Loyola University Medical Center Maywood Illinois
United States Saint Anthony Memorial Health Centers Michigan City Indiana
United States Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center Milford Massachusetts
United States Wheaton Franciscan Cancer Care - St. Joseph Milwaukee Wisconsin
United States Hennepin County Medical Center - Minneapolis Minneapolis Minnesota
United States Virginia Piper Cancer Institute at Abbott - Northwestern Hospital Minneapolis Minnesota
United States Michiana Hematology-Oncology, PC - South Bend Mishawaka Indiana
United States Saint Joseph Regional Medical Center Mishawaka Indiana
United States Montana Cancer Center at St. Patrick Hospital and Health Sciences Center Missoula Montana
United States Montana Cancer Specialists at Montana Cancer Center Missoula Montana
United States Providence Cancer Center at Providence Hospital Mobile Alabama
United States Community Cancer Center of Monroe Monroe Michigan
United States Louisiana State University Health Sciences Center - Monroe Monroe Louisiana
United States Mercy Memorial Hospital - Monroe Monroe Michigan
United States Skagit Valley Hospital Cancer Care Center Mount Vernon Washington
United States Jon and Karen Huntsman Cancer Center at Intermountain Medical Center Murray Utah
United States MBCCOP - Meharry Medical College - Nashville Nashville Tennessee
United States Yale Cancer Center New Haven Connecticut
United States MBCCOP - LSU Health Sciences Center New Orleans Louisiana
United States Medical Center of Louisiana - New Orleans New Orleans Louisiana
United States New York Weill Cornell Cancer Center at Cornell University New York New York
United States Michiana Hematology Oncology PC - Niles Niles Michigan
United States Callahan Cancer Center at Great Plains Regional Medical Center North Platte Nebraska
United States Fisher-Titus Medical Center Norwalk Ohio
United States Green Bay Oncology, Limited - Oconto Falls Oconto Falls Wisconsin
United States Val and Ann Browning Cancer Center at McKay-Dee Hospital Center Ogden Utah
United States Oklahoma University Cancer Institute Oklahoma City Oklahoma
United States Alegant Health Cancer Center at Bergan Mercy Medical Center Omaha Nebraska
United States CCOP - Missouri Valley Cancer Consortium Omaha Nebraska
United States Creighton University Medical Center Omaha Nebraska
United States Immanuel Medical Center Omaha Nebraska
United States Lakeside Hospital Omaha Nebraska
United States Methodist Estabrook Cancer Center Omaha Nebraska
United States UNMC Eppley Cancer Center at the University of Nebraska Medical Center Omaha Nebraska
United States St. Charles Mercy Hospital Oregon Ohio
United States Toledo Clinic - Oregon Oregon Ohio
United States Granville Medical Center Oxford North Carolina
United States Michiana Hematology Oncology PC - Plymouth Plymouth Indiana
United States Robert and Beverly Lewis Family Cancer Care Center at Pomona Valley Hospital Medical Center Pomona California
United States Kaiser Permanente Health Care - Portland Portland Oregon
United States Utah Valley Regional Medical Center - Provo Provo Utah
United States Duke Health Raleigh Hospital Raleigh North Carolina
United States Humphrey Cancer Center at North Memorial Outpatient Center Robbinsdale Minnesota
United States Kaiser Permanente Capital Area Medical Group - Shady Grove Facility Rockville Maryland
United States Person Memorial Hospital Roxboro North Carolina
United States Dixie Regional Medical Center - East Campus Saint George Utah
United States Saint Helena Hospital Saint Helena California
United States Lakeland Regional Cancer Care Center - St. Joseph Saint Joseph Michigan
United States Lakeside Cancer Specialists, PLLC Saint Joseph Michigan
United States Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis Saint Louis Missouri
United States CCOP - Metro-Minnesota Saint Louis Park Minnesota
United States Park Nicollet Cancer Center Saint Louis Park Minnesota
United States Regions Hospital Cancer Care Center Saint Paul Minnesota
United States United Hospital Saint Paul Minnesota
United States Salinas Valley Memorial Hospital Salinas California
United States Huntsman Cancer Institute at University of Utah Salt Lake City Utah
United States LDS Hospital Salt Lake City Utah
United States Utah Cancer Specialists at UCS Cancer Center Salt Lake City Utah
United States UCSF Helen Diller Family Comprehensive Cancer Center San Francisco California
United States North Coast Cancer Care, Incorporated Sandusky Ohio
United States Nancy N. and J. C. Lewis Cancer and Research Pavilion at St. Joseph's/Candler Savannah Georgia
United States Mercy Hospital Cancer Center - Scranton Scranton Pennsylvania
United States Group Health Central Hospital Seattle Washington
United States Minor and James Medical, PLLC Seattle Washington
United States Swedish Cancer Institute at Swedish Medical Center - First Hill Campus Seattle Washington
United States University Cancer Center at University of Washington Medical Center Seattle Washington
United States North Puget Oncology at United General Hospital Sedro-Woolley Washington
United States St. Nicholas Hospital Sheboygan Wisconsin
United States Welch Cancer Center at Sheridan Memorial Hospital Sheridan Wyoming
United States Feist-Weiller Cancer Center at Louisiana State University Health Sciences Shreveport Louisiana
United States Highland Clinic Shreveport Louisiana
United States CCOP - Northern Indiana CR Consortium South Bend Indiana
United States Memorial Hospital of South Bend South Bend Indiana
United States Cancer Care Northwest - Spokane South Spokane Washington
United States Evergreen Hematology and Oncology, PS Spokane Washington
United States Rockwood Clinic Cancer Treatment Center Spokane Washington
United States Lakeview Hospital Stillwater Minnesota
United States Green Bay Oncology, Limited - Sturgeon Bay Sturgeon Bay Wisconsin
United States Flower Hospital Cancer Center Sylvania Ohio
United States SUNY Upstate Medical University Hospital Syracuse New York
United States Veterans Affairs Medical Center - Syracuse Syracuse New York
United States Mercy Hospital of Tiffin Tiffin Ohio
United States CCOP - Toledo Community Hospital Toledo Ohio
United States Medical University of Ohio Cancer Center Toledo Ohio
United States St. Anne Mercy Hospital Toledo Ohio
United States St. Vincent Mercy Medical Center Toledo Ohio
United States Toledo Clinic, Incorporated - Main Clinic Toledo Ohio
United States Toledo Hospital Toledo Ohio
United States Cotton-O'Neil Cancer Center Topeka Kansas
United States Carle Cancer Center at Carle Foundation Hospital Urbana Illinois
United States CCOP - Carle Cancer Center Urbana Illinois
United States Franklin & Edith Scarpa Regional Cancer Center at South Jersey Healthcare Vineland New Jersey
United States Ridgeview Medical Center Waconia Minnesota
United States Pacific Cancer Institute - Maui Wailuku Hawaii
United States Kaiser Permanente at Capitol Hill Medical Center Washington District of Columbia
United States Lombardi Comprehensive Cancer Center at Georgetown University Medical Center Washington District of Columbia
United States Covenant Cancer Treatment Center Waterloo Iowa
United States University of Wisconcin Cancer Center at Aspirus Wausau Hospital Wausau Wisconsin
United States Fulton County Health Center Wauseon Ohio
United States Wenatchee Valley Medical Center Wenatchee Washington
United States Veterans Affairs Medical Center - West Haven West Haven Connecticut
United States Michiana Hematology Oncology PC - La Porte Westville Indiana
United States Ruby L. Golleher Cancer Program at Presbyterian Intercommunity Hospital Whittier California
United States Susquehanna Cancer Center at Divine Providence Hospital Williamsport Pennsylvania
United States Willmar Cancer Center at Rice Memorial Hospital Willmar Minnesota
United States Riverview UW Cancer Center at Riverview Hospital Wisconsin Rapids Wisconsin
United States Minnesota Oncology Hematology, PA - Woodbury Woodbury Minnesota

Sponsors (6)

Lead Sponsor Collaborator
Alliance for Clinical Trials in Oncology Eastern Cooperative Oncology Group, National Cancer Institute (NCI), NCIC Clinical Trials Group, Novartis Pharmaceuticals, Southwest Oncology Group

Countries where clinical trial is conducted

United States,  Canada, 

References & Publications (1)

Smith MR, Halabi S, Ryan CJ, Hussain A, Vogelzang N, Stadler W, Hauke RJ, Monk JP, Saylor P, Bhoopalam N, Saad F, Sanford B, Kelly WK, Morris M, Small EJ. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cance — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Time to First Skeletal Related Event Time to first skeletal related event (SRE) was defined as the time from randomization to first skeletal event. Skeletal events are defined as radiation to bone, clinical fracture, surgery to bone and spinal cord compression and death due to prostate cancer. The median with 95% CI was estimated using the Kaplan Meier method. Up to 10 years
Secondary Overall Survival Overall survival (OS) was defined as the time from randomization to death of any cause. Surviving patients were censored at the date of last follow-up. The median OS with 95% CI was estimated using the Kaplan Meier method. Up to 10 years
Secondary Progression-free Survival Progression Free Survival (PFS) was defined as the time from registration until disease progression or death, whichever occurs first. The median PFS with 95% CI was estimated using the Kaplan-Meier method.
Progression is defined as one or more of the following: new bone metastases, biochemical progression of PSA, treatment with radiation therapy while on treatment.
Up to 10 years
See also
  Status Clinical Trial Phase
Recruiting NCT05540392 - An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues Phase 1/Phase 2
Recruiting NCT05613023 - A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT Phase 3
Recruiting NCT05156424 - A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Phase 1/Phase 2
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT01331083 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05540782 - A Study of Cognitive Health in Survivors of Prostate Cancer
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT06305832 - Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05761093 - Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A